1. Home
  2. PHGE vs PRPH Comparison

PHGE vs PRPH Comparison

Compare PHGE & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • PRPH
  • Stock Information
  • Founded
  • PHGE 2015
  • PRPH 1989
  • Country
  • PHGE Israel
  • PRPH United States
  • Employees
  • PHGE N/A
  • PRPH N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • PRPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • PHGE Health Care
  • PRPH Health Care
  • Exchange
  • PHGE Nasdaq
  • PRPH Nasdaq
  • Market Cap
  • PHGE 13.3M
  • PRPH 10.7M
  • IPO Year
  • PHGE N/A
  • PRPH 1997
  • Fundamental
  • Price
  • PHGE $0.63
  • PRPH $0.39
  • Analyst Decision
  • PHGE Strong Buy
  • PRPH
  • Analyst Count
  • PHGE 2
  • PRPH 0
  • Target Price
  • PHGE $23.00
  • PRPH N/A
  • AVG Volume (30 Days)
  • PHGE 117.4K
  • PRPH 1.7M
  • Earning Date
  • PHGE 05-19-2025
  • PRPH 03-31-2025
  • Dividend Yield
  • PHGE N/A
  • PRPH N/A
  • EPS Growth
  • PHGE N/A
  • PRPH N/A
  • EPS
  • PHGE N/A
  • PRPH N/A
  • Revenue
  • PHGE N/A
  • PRPH $6,770,000.00
  • Revenue This Year
  • PHGE N/A
  • PRPH N/A
  • Revenue Next Year
  • PHGE N/A
  • PRPH $64.06
  • P/E Ratio
  • PHGE N/A
  • PRPH N/A
  • Revenue Growth
  • PHGE N/A
  • PRPH N/A
  • 52 Week Low
  • PHGE $0.48
  • PRPH $0.22
  • 52 Week High
  • PHGE $4.99
  • PRPH $7.48
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 49.87
  • PRPH 45.88
  • Support Level
  • PHGE $0.48
  • PRPH $0.35
  • Resistance Level
  • PHGE $0.58
  • PRPH $0.60
  • Average True Range (ATR)
  • PHGE 0.06
  • PRPH 0.08
  • MACD
  • PHGE 0.00
  • PRPH 0.00
  • Stochastic Oscillator
  • PHGE 68.16
  • PRPH 27.59

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

About PRPH ProPhase Labs Inc. (DE)

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Share on Social Networks: